PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16912036-6 2006 Substitution of the SH3-SH2 tyrosine phosphorylation sites with phenylalanine substantially reduced Bcr-Abl-mediated transformation of TF-1 myeloid cells to cytokine independence. Phenylalanine 64-77 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 100-107 16943190-6 2006 Moreover, we show that activated Abl phosphorylates the EGFR primarily on tyrosine 1173, and that mutation of this site to phenylalanine restores ligand-dependent endocytosis of the EGFR in the presence of activated Abl. Phenylalanine 123-136 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 216-219 8510937-0 1993 Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl. Phenylalanine 14-27 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 111-116 12149456-3 2002 Here we identify mutations of Tyr-253 in the nucleotide-binding (P) loop of the Abl kinase domain to Phe or His in patients with advanced CML and acquired STI-571 resistance. Phenylalanine 101-104 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 80-83 12833568-5 2003 High-resolution affinity panning coupled with mass spectrometric readout allows for quick identification of Trp as the preferred fourth residue in the decapeptide ligand APTWSPPPPP, which binds to Abl SH3 four times stronger than does the decapeptide containing Tyr or Phe in the fourth position. Phenylalanine 269-272 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 197-200 8510937-4 1993 Phenylalanine 420 is perfectly conserved among tyrosine kinases with N-terminal SH3 domains (the Src and Abl families). Phenylalanine 0-13 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 105-108 8510937-6 1993 Mutation of phenylalanine 420 to other hydrophobic residues activates c-Abl. Phenylalanine 12-25 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 70-75 22314840-4 2012 Multiple rational design cycles were utilized to develop a lead peptide with a phenylalanine and alanine replaced by an (N-methyl)phenylalanine and isoleucine, respectively, to attain cytosolic peptidase resistance while maintaining Abl substrate efficacy. Phenylalanine 79-92 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 233-236 25348715-4 2015 We identified a selected number of Phe mutations in a small group of kinases that included BRAF, ABL1, and the epidermal growth factor receptor. Phenylalanine 35-38 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 97-101 33932144-3 2021 In this study, we demonstrate that c-Abl highly phosphorylates FHL2 at Y97, Y176, Y217 and Y236 through mass spectrometry and tyrosine-to-phenylalanine (Y F) mutant analysis. Phenylalanine 138-151 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 35-40 30177833-5 2019 Replacement of the three tyrosine residues Tyr-524, -610, and -1048 with phenylalanine (3YF) inhibits c-Abl-mediated phosphorylation of TIF1gamma and enhances TIF1gamma"s association with Smad3. Phenylalanine 73-86 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 102-107 18436994-4 2008 The sequencing of BCR-ABL kinase domains was performed and revealed the presence of a F359I point mutation (TTC-to-ATC nucleotide change leading to Phe-to-Ile amino acid substitution). Phenylalanine 148-151 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 18-25